Added to basket
Unapplied Changes
Croma-Pharma is proud to announce the launch of Exprecell™, an MDR-approved all-in-one medical system for the preparation of autologous Platelet-Rich Plasma (PRP) | Fluid-Platelet-Rich Fibrin (Fluid-PRF).¹
With its innovative design and optimised separation technology, Exprecell™ enables the efficient preparation of autologous blood concentrates without the use of anticoagulants.¹ This results in the formation of Fluid-PRF, a biologically active concentrate that retains the regenerative properties of platelets and leukocytes while remaining liquid for a defined period of time.¹ The high capacity single syringe system for blood aspiration and the subsequent single spin process, allows PRP preparation from whole blood within 5-minutes spin time.
KEY BENEFITS
◆ Anticoagulant-Free
The preparation of PRP without the use of anticoagulants results in the formation of Fluid-PRF, that stays liquid for a certain period of time.1
◆ Delivers Platelet Concentration Within The Optimal Range2,3
2.3-foldb platelets over baseline were observed, based on study data.1
◆ Fast & Easy Preparation In One System
All-in-one medical device, designed for blood aspiration and subsequent single spin process, enabling PRP preparation from whole blood within 5-minute spin time.1
◆ Contains Extracellular Vesicles (Such As Exosomes)
Majority (86%) of EVs are platelet-derived.1
◆ Made In Austria
Exprecell™ Single Syringe System – premium-quality medical device made in Austria, compliant with DIN ISO 13485 standards.1
◆ High-Capacity Syringe For Efficient Preparation
18 mL of whole blood yield approx. 8.5 mLa of autologous PRP | Fluid-PRF.1
PRODUCT PERFORMANCE1
● Platelet concentration factor: 2.3-fold increase from baselineb
● Fluid-PRF yield: ≈ 8.5 mLa
● Leukocyte (WBC) reduction: 95%
● Erythrocyte (RBC) reduction: 99%
● Platelet recovery: 52–96%d
● Extracellular vesicles (e.g. exosomes):
≈ 7.5 million EVs/mLc
“We are delighted to announce the addition of Exprecell™ to our portfolio, offering a next-generation solution for fast, anticoagulant-free preparation of PRP. This launch represents Croma’s continued mission to provide healthcare professionals with state-of-the-art tools that support clinical performance, efficiency, and quality of care.”
Vikki Baker, Commercial Director Netherlands & Nordics
Croma-Pharma UK
“I am proud to be one of the first practitioners to offer Exprecell™ in the UK. With the growing patient demand for regenerative treatments, it’s exciting to provide an MDR approved solution for autologous Platelet-Rich Plasma (PRP) and Fluid Platelet-Rich Fibrin (Fluid-PRF).”
Dr Munir Somji, Global KOL
* For full instructions, please refer to the IFU.
1 Data on file. 2 Graziani F, Ivanovski S, Cei S, Ducci F, Tonetti M, Gabriele M. The in vitro effect of different PRP concentrations on osteoblasts and fibroblasts. Clin Oral Implants Res. 2006 Apr;17(2):212-219. doi:10.1111/j.1600-0501.2005.01203.x. PMID:16584418. 3 Anitua E, S.nchez M, Zalduendo MM, de la Fuente M, Prado R, Orive G, And.a I. Fibroblastic response to treatment with different preparations rich in growth factors. Cell Prolif. 2009
Apr;42(2):162-170. doi:10.1111/j.1365- 2184.2009.00583.x. PMID:19250293. PMCID:PMC6496288 EXFS092025.
a Median total PRP yield: 8.5 mL (range: 6.5–10.5 mL). b Median platelet concentration factor: 2.3 (range: 1.55–3.34). c Median EVs/mL ≈ 7.5 × 10⁶
(range: ~5 × 10⁶ – 1 × 10⁷). d Ratio of total platelets recovered in the concentrate to total platelets present in baseline sample
The healthcare professional confirms having informed the patient of a likely risk associated with the use of the medical device in line with its intended use.For risks and adverse events associated with the use of the medical device consult the instructions of use. CE 2797
Croma-Pharma® is a global player in the minimally invasive aesthetics market and a leading European manufacturer of premium quality hyaluronic acid syringes. The company offers a comprehensive and innovative aesthetics portfolio including hyaluronic acid fillers, PDO threads and biostimulators complemented by its own skincare brand. Founded in 1976 by pharmacist couple Gerhard and Karin Prinz in Vienna, Croma is a family company headquartered in Austria where it also operates its manufacturing plant. With 550 employees, 15 subsidiaries in Europe and Brazil, two joint ventures and 60 exclusive export partners, it distributes its products in 80 markets globally, including the USA/Canada, China and Australia/New Zealand. Croma also operates as a hyaluronic acid contract manufacturer for orthopaedics and ophthalmology. For more information please visit cromapharma.com.
info.uk@cromapharma.com
https://www.cromapharma.com/uk/
